Table 1 Demographic, treatment variables and clinical risk factors in the study patients (n = 246).
Variable | Total group (n = 246) |
|---|---|
Age (years) | 44 ± 12.4 |
Males/premenopausal women/postmenopausal women | 109/103/34 (44/42/14) |
Body mass index (kg/m2) | 25.5 ± 4.7 |
Sarcoidosis/CD/UC | 87/95/64 (35/39/26) |
Disease duration (years) | 6 (1–36) |
GC use never/previous/current | 74/124/48 (30/50/20) |
Daily dose GC current group | 12.9 (2.5–39) |
Fracture > 50 years, number | 2/83 (2) |
Vertebral deformity by DXA | 54 (22) |
Low body weight (< 60 kg) | 44 (18) |
Low physical activity index ≤ 5 | 53 (22) |
Mother with hip deformity | 16 (7) |